BlackRock’s Apexigen, Inc. Common Stock APGN Stock Holding History

BlackRock’s Portfolio APGN Stock Details APGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-213,833	Closed	-$91.9K	–	5588
2023 Q2	$91.9K	Hold	213,833	–	–	﹤0.01%	4938
2023 Q1	$104K	Hold	213,833	–	–	﹤0.01%	4942
2022 Q4	$146K	Hold	213,833	–	–	﹤0.01%	4936
2022 Q3	$577K	Buy	+213,833	New	+$1.74M	﹤0.01%	4676

BlackRock's APGN Position: Q3 2023 in Review

BlackRock sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2023, closing a stake of 213,833 shares — an estimated $91.9K sold.

BlackRock first reported a position in APGN in Q3 2022 and held it in 4 quarters. The position peaked at $577K in Q3 2022. 0 funds tracked by Wall St. Rank hold APGN as of Q3 2023.

BlackRock reported no remaining Apexigen, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 213,833 Apexigen, Inc. Common Stock shares in Q3 2023, an estimated $91.9K.
BlackRock first reported a position in Apexigen, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
BlackRock's Apexigen, Inc. Common Stock position peaked at $577K in Q3 2022.
0 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.